Selecting a medical-grade epoxy adhesive and demonstrating that it performs adequately in the intended application are two separate activities, and both are required for FDA submissions for devices where adhesive bonding is a critical assembly method. Selection based on supplier data sheets establishes that the material has the right properties in general; qualification testing on the specific joint design, substrate combination, and environmental exposure of the actual device establishes that the specific implementation works. Building the documentation that connects these two activities into a coherent, FDA-ready package requires understanding what types of evidence the agency expects to see, how that evidence is organized, and where the gaps in supplier-provided data require device-level testing to fill.
What FDA Expects for Material and Process Documentation
FDA’s technical requirements for device regulatory submissions do not specify exactly what tests must be run for adhesive bonds — they require that the manufacturer demonstrate the device is safe and effective through “valid scientific evidence.” For structural adhesive bonds, valid scientific evidence consists of test data showing that the bond meets the design requirements under the conditions the device will actually encounter — not just at ambient conditions with fresh material.
The Design History File (DHF) for the device must document: the design requirement for the bond (minimum strength, maximum allowable displacement, required service life), the rationale for selecting the adhesive (why this material meets the requirement), the testing performed to verify the design, and the results confirming that the design requirements are met. Each element must be documented and cross-referenced so that a reviewer can follow the logical chain from requirement to evidence.
For 510(k) submissions, the device description section includes materials of construction. The submission should reference the adhesive by product name and indicate where documentation of its safety and performance can be found — typically in the design verification testing section and the biocompatibility section. For PMAs, the evidence requirements are more detailed, and design verification testing results may need to be summarized in the submission rather than simply referenced.
Design Verification Testing for Adhesive Bonds
Design verification testing for adhesive bonds confirms that the joint design meets the design requirements under specified conditions. The test matrix should include:
Mechanical strength testing at ambient conditions: Lap shear strength (ASTM D1002 or ISO 4587) on test specimens prepared with the production surface preparation, production adhesive, production cure schedule, and the substrate materials used in the device. This establishes the baseline strength before environmental conditioning.
Mechanical strength after environmental conditioning: The same specimens or companion specimens tested after conditioning that simulates device service conditions — autoclave cycling for reusable devices (typically 200 to 500 cycles at the worst-case sterilization temperature), chemical soak in relevant cleaning agents, humidity aging, or temperature cycling as applicable. The retention of required strength after conditioning is the critical result.
Mechanical strength over the device design life: For devices with long service lives (5 to 10 years), the conditioning program must demonstrate performance through the full design life, either by direct testing through the design life or by accelerated aging with validated acceleration factor.
For specific test protocols, conditioning parameters, and testing laboratory support for adhesive bond qualification in your device, Email Us — Incure can provide test data on standard substrate combinations and support custom testing for device-specific configurations.
Acceptance Criteria Derivation
The design requirement for a structural bond must be quantitative — a minimum strength value that the bond must meet — and the acceptance criteria for verification testing must be derived from this requirement with appropriate statistical treatment.
The design load on the bond — the maximum force the bond must withstand in service — is determined from the device mechanics: what forces are applied to the bonded joint during normal use, during reasonably foreseeable misuse, and during any test load the device must survive (drop test, vibration test). The required bond strength is the design load divided by the bond area, multiplied by the required safety factor.
For medical device structural bonds, safety factors of 4 to 6 are common for permanent bonds in non-life-supporting applications, with higher factors for life-supporting or high-consequence applications. A bond that must withstand 20 N in use with a safety factor of 5 requires a design bond strength of 100 N.
The verification acceptance criterion is: the mean measured strength minus some statistical margin (typically based on the design-of-experiments or tolerance analysis approach used in the design) must exceed the design bond strength. Simply measuring a few samples and reporting the mean is not sufficient; the acceptance criterion must account for the natural variability in bond strength across production samples.
Biocompatibility Documentation in the Submission
The biocompatibility section of the submission must address all materials in the device that contact the patient — directly or through fluid-contact pathways. For adhesive bonds, this means:
Identifying the specific adhesive formulation (product name, manufacturer, product number) and confirming it is the exact formulation used in the device — not a similar product, not a different lot formulation.
Referencing the ISO 10993 test reports for the formulation. If the supplier has conducted the testing, the reports are referenced in the submission; if the reports exist only as summaries, the full reports should be in the design history file and referenced.
Documenting the biological evaluation plan and report that applies the ISO 10993 framework to the specific device contact configuration — confirming that the contact category and duration for the adhesive use are within the tested conditions.
Confirming that the biocompatibility testing was conducted on the adhesive at the production cure schedule. If the cure conditions in the device differ from the cure conditions used in biocompatibility testing, the biological evaluation must address this discrepancy.
Change Control After Submission Clearance
After a device is cleared or approved by FDA, changes to materials — including the adhesive — require evaluation under the device change control procedures. For adhesive changes, the change control must assess whether the change affects safety or effectiveness (which could require a new 510(k) or PMA supplement) or is a minor change within the device’s approved specifications.
Changes that typically require regulatory notification include: changing to a different adhesive product, using a reformulated version of the same product where the formulation change affects biocompatibility or mechanical properties, or changing the cure process in a way that affects the final adhesive properties. Working with a supplier who maintains a stable, well-documented formulation — and notifies customers of any formulation changes — reduces the change control burden for device manufacturers.
Contact Our Team to discuss adhesive qualification test programs, documentation support, biocompatibility data packages, and change control considerations for FDA submissions for your medical device.
Visit www.incurelab.com for more information.